ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, and MilliporeSigma have entered a global license agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations.   MilliporeSigma and ReForm Biologics will conduct research, development and qualification of ReForm Biologics’ excipients for pharmaceutical use. MilliporeSigma will fund the research and development and be responsible...